Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Improving Response Assessment in Cancer by Measurement of Cellular Redox Status Using 18F-FSPG Positron Emission Tomography
Guy's and St Thomas' NHS Foundation Trust
32 participants
Feb 19, 2025
OBSERVATIONAL
Conditions
Summary
Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.
Eligibility
Inclusion Criteria5
- Written informed consent
- Aged 16 or above
- Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy)
- Willingness and ability to comply with scheduled study visits and tests
- Confirmation of adequate function of all major organs and systems
Exclusion Criteria5
- Pregnant or lactating women
- Concomitant uncontrolled medical conditions
- Participants likely to require palliative radiotherapy within the first 12 weeks of treatment
- Prognosis less than 3 months
- Previous anti-cancer treatment (only treatment naïve patients eligible for inclusion)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05889312